All results are stated before exceptional items and goodwill amortisation
and in UK GAAP. Trading profit represents operating profit before
R&D. All growth rates stated at constant exchange unless otherwise
noted.
6 months
to 30 June
2002
£m
6 months
to 30 June
2001
£m
Growth at
constant
exchange
rate (CER)
%
Growth
at actual
exchange
rate
%
Sales
812
783
7#
4
Operating profit†
165
143
15
15
Profit before tax†
159
138
15
15
EPS†
15.5p
13.4p*
19
16
Dividend per share
2.65p
2.35p
n/a
13
Highlights
Sales up 7%# to £812m, operating
profit up 15% to £165m driven by 2% improvement in operating margin,
earnings per share up 19% and dividend per share up 13%
Good growth in medical diagnostics:
– Continued strong growth in portfolio of patented products, sales
up 21% to £171m
– Sales of unpatented products up 6% to £188m, with sales of Omnipaque™
up 9% to £117m
Protein separations sales up 12%#
to £131m
Discovery systems sales up 3%#
to £202m
Operating cash flow† increased by £29m to £134m
†
Before exceptional items and goodwill amortisation.
After exceptional items and goodwill amortisation, operating
profit was £150m up from £143m in the first half of 2001, profit
before tax was £144m up from £137m, and earnings per share were
14.9p up from 13.6p.
